For more than ten years trastuzumab has represented the only approved targeted treatment for HER2-positive GC, with several phase II and III clinical trials evaluating other HER2-targeted agents such as lapatinib, T-DM1, and pertuzumab failing to meet their primary endpoints. The gene discussed is ERBB2; the disease is gastric cancer.